Selank Peptide Reduces Inflammatory Cytokines in Socially Stressed Animals
Background
Chronic exposure to social stress is a significant contributor to various mental health disorders, including anxiety and depression. This stress often triggers an overactive immune response, characterized by elevated levels of cytokines, which are signaling proteins that regulate inflammation. An imbalance in these cytokines, particularly an increase in pro-inflammatory markers, is linked to the pathophysiology of stress-related conditions. Despite its known anxiolytic effects, the specific impact of the peptide Selank on stress-induced cytokine dysregulation remained underexplored.
Results
The study revealed that social defeat stress significantly altered cytokine profiles in untreated animals, leading to a marked increase in pro-inflammatory markers. Specifically, the stress-only group showed a 62% increase in IL-6 and a 55% increase in TNF-α compared to controls (p<0.001 for both). Conversely, the anti-inflammatory IL-10 was reduced by 35% in the stress-only group (p<0.01).
Why It Matters
Selank's ability to normalize cytokine profiles under social stress conditions suggests its potential as a novel therapeutic agent for stress-related inflammatory disorders. This immunomodulatory effect could be particularly beneficial in conditions where chronic stress exacerbates inflammation, such as anxiety disorders, depression, and even certain neurodegenerative diseases. The findings provide strong preclinical evidence supporting the further investigation of Selank for clinical applications in managing stress-induced immune dysregulation. Future research should focus on dose-response studies, long-term effects, and ultimately, human clinical trials (Phase II) to confirm these promising results.